학술논문

Cost‐utility analysis of the National Health Screening Program for chronic kidney disease in Korea.
Document Type
Article
Source
Nephrology. Jan2019, Vol. 24 Issue 1, p56-64. 9p.
Subject
*KIDNEY diseases
*MEDICAL screening
*MEDICAL care
*MARKOV processes
*DISEASE progression
Language
ISSN
1320-5358
Abstract
Aim: Although a National Health Screening Program (NHSP) for chronic kidney disease (CKD) has been implemented in Korea since 2002, its cost‐effectiveness has never been determined. This study aimed to estimate the cost‐utility of NHSP for CKD in Korea. Methods: A Markov decision analytic model was constructed to compare CKD screening strategies of the NHSP with no screening. We developed a model that simulated disease progression in a cohort aged 20–120 years or death from the societal perspective. Results: Biannual screening starting at age 40 for CKD by proteinuria (dipstick) and estimated glomerular filtration ratio had an ICUR of $66 874/QALY relative to no screening. The targeted screening strategy had an ICUR of $37 812/QALY and $40 787/QALY for persons with diabetes and hypertension, respectively. ICURs improved with lower cost strategies. The most influential parameter that might make screening more cost‐effective was the effectiveness of treatment on CKD to decrease disease progression and mortality. Conclusions: The Korean NHSP for CKD is more cost‐effective for patients with diabetes or hypertension than the general population, consistent with prior studies. Although it is too early to conclude the cost‐effectiveness of the Korean NHSP for CKD, this study provides evidence that is useful in evaluating the cost‐effectiveness of CKD interventions. Summary at a Glance: The authors successfully demonstrate that the Korean National Health Screening Program (NHSP) for CKD is more cost‐effective for patients with diabetes or hypertension than the general population. [ABSTRACT FROM AUTHOR]